Before the emergence of data from the SUNLIGHT trial, there were only 2 options for therapy in advanced colorectal cancer: ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS Joenja® is the first and only medicine specifically for APDS to be reimbursed within the ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Leiden, the Netherlands Thursday, April 24, 2025, 10:00 Hrs [IST] ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small ...

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS ...

Lipid metabolism has emerged as a central player in the progression and therapy resistance of breast cancer, particularly the aggressive subtype ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

tumor invasion and neo-angiogenesis. Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the ...

H., Liu Y., Borden E., Jain M. K., and Kao H. Y. “Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon alpha-mediated inhibition of angiogenesis” J Biol ...